Glimepirid Stada

Glimepirid Stada is a prescription medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent. It is marketed in the European Union under the brand name Glimepirid Stada. The product is supplied as an oral tablet, though specific strength and dosage form details are not disclosed in this summary. Glimepiride works by stimulating insulin release from pancreatic beta cells to help control blood glucose levels in type 2 diabetes.

Glimepirid Stada is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

- Used as monotherapy when diet, exercise, and weight control are insufficient. - Combined with metformin or other oral antidiabetic agents to improve glycemic control. - May be prescribed when a patient requires a sulfonylurea with a longer duration of action. - Considered for patients who have stable renal function and no history of severe hypoglycemia. - Utilized in treatment plans aiming to reduce HbA1c levels alongside lifestyle modifications.

The safety profile of Glimepirid Stada reflects the typical effects observed with sulfonylureas, ranging from mild, frequently reported events to rare but serious reactions.

Common: - Mild to moderate hypoglycemia, often presenting as shakiness, sweating, or hunger when meals are missed. - Nausea, occasional vomiting, or general abdominal discomfort. - Headache, light‑headedness, or transient dizziness. - Gradual weight gain associated with improved insulin secretion. - Transient elevations in liver enzymes detected on routine laboratory testing.

Serious: - Severe hypoglycemia that may cause loss of consciousness, seizures, or require emergency assistance. - Allergic responses including widespread rash, itching, swelling of the face, lips, tongue, or throat (angio‑edema).

When prescribing Glimepirid Stada, clinicians should evaluate several precautionary factors to minimize risks and ensure appropriate use in patients with type 2 diabetes.

- Assess renal and hepatic function before initiation; dose adjustments may be needed in impairment. - Review patient history for prior sulfonylurea‑induced hypoglycemia or allergic reactions. - Use caution in elderly patients, who may be more susceptible to hypoglycemia. - Avoid use during pregnancy or lactation unless benefits clearly outweigh potential risks. - Monitor blood glucose regularly, especially when starting therapy or changing doses. - Educate patients on recognizing and managing hypoglycemia symptoms.

Glimepirid Stada can interact with several medications, affecting glucose control or increasing the risk of adverse events; awareness of these interactions guides safe co‑administration.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride plasma levels. - High‑dose salicylates (e.g., aspirin >3 g/day) that potentiate hypoglycemic effect.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, as they can impair glucose tolerance. - ACE inhibitors or ARBs, requiring monitoring of renal function and electrolytes. - Antidepressants like SSRIs, which have been reported to alter glycemic control.